The AlphaLISA® SureFire® Ultra™ Multiplex phospho-ERK1/2 (Thr202/Tyr204) + Total ERK assay kit is used to measure both the phosphorylation of ERK1/2 and total levels of endogenous ERK1/2 in cellular lysates. The assay is an ideal system for the screening of modulators of receptor activation (e.g. agonists and antagonists) as well as agents acting intracellularly, such as small molecule inhibitors of signal transduction. The assay will measure ERK1/2phosphorylation by either recombinant or endogenous receptors and can be applied to primary cells.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The Alpha SureFire® Ultra™ Multiplex p-ERK1/2 (Thr202/Tyr204) (Eu) + Total ERK (Tb)assay kit is used to measure both phosphorylated and total levels of endogenous ERK1/2 in cellular lysates in a multiplexing Alpha no-wash assay. No specially engineered cell lines are required. The 615 nm (Eu) signal corresponds to the phosphorylated ERK1/2 analysis, and the 545 nm (Tb) signal corresponds to the total ERK1/2 nalysis. This kit has been formulated to provide superior signal:background assay windows and to perform without interference in the presence of extraneous antibodies, making it amenable to the study of therapeutic and blocking antibodies.
In this assay, the Alpha 615 Acceptor bead is coated with the CaptSure™ antibody, which binds the CaptSure-tagged anti-phospho target antibody. The Alpha 545 Acceptor bead is coated with the CaptSure2™ agent, which binds the CaptSure2 tagged anti-total target protein antibody. The Alpha Donor bead binds the biotinylated anti-total target protein antibody.
|Assay Target Class||Phosphoprotein, Protein|
|Experimental Type||In vitro|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.